Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.

Autor: Iso, Hirokazu (AUTHOR), Miyanaga, Akihiko (AUTHOR), Kadoma, Naohiro (AUTHOR), Shinbu, Kaoruko (AUTHOR), Tozuka, Takehiro (AUTHOR), Murata, Akari (AUTHOR), Nishima, Shunichi (AUTHOR), Sato, Yozo (AUTHOR), Nakamichi, Shinji (AUTHOR), Matsumoto, Masaru (AUTHOR), Noro, Rintaro (AUTHOR), Terasaki, Yasuhiro (AUTHOR), Kubota, Kaoru (AUTHOR), Seike, Masahiro (AUTHOR)
Zdroj: OncoTargets & Therapy. Jun2023, Vol. 16, p465-470. 6p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje